RE:Comparisons of single agents From the percentages used, we can see that they are counting the 4 patients from the 1st set of 12 who got a second optimized treatment but not a first. 27 patients total. Affects the long term results as they will not have received 2 optimized treatments, but only 1. IMO. Plus we have one patient who sadly passed away and is included. So at 450 days in Optimized group, we have 1 patient who passed away, 4 patients who only got one out of 2 optimized treatments and 1 who is CR and 1 PR. So 7 out 27 reached 450 days, but these are the least representative of Optimized patients in the Optimized group, with 5 out of 7 being either the 1 who passed away or 4 with only one instead of 2 optimized treatments. This data report may pave the way for significant improvement in the next reports to come and finally get the ball rolling. I still expect 65-75% CR at 3 months and 35-45% CR at 12-15 months, and that would be phenomenal and bettter than any other single agent and as good or better than most combination treatments with far fewer treatments. All IMO
enriquesuave wrote:
90 days 12 months # of treatments in 12 months period
Keytruda. 41%. 19%. 18. IV
Vicinium. 42%. 17%. 36
Adstiladrin. 50%. 24%. 4
TLD-1433. 50%. 25%. 2. Non optimized evaluable patients
TLD-1433. 60%. 11.1%. 2. Too early to assess not enough data
Data is beating all single agents and potential for PR patients to convert to CR status increases the potential to beat present data.